DrugPatentWatch Database Preview
Janssen R And D Company Profile
What is the competitive landscape for JANSSEN R AND D, and when can generic versions of JANSSEN R AND D drugs launch?
There are four US patents protecting JANSSEN R AND D drugs.
There are one hundred and thirty-four patent family members on JANSSEN R AND D drugs in thirty-nine countries and twelve supplementary protection certificates in eleven countries.
Summary for Janssen R And D
| International Patents: | 134 |
| US Patents: | 4 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Janssen R And D
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen R And D | INTELENCE | etravirine | TABLET;ORAL | 022187-002 | Dec 22, 2010 | RX | Yes | Yes | 7,037,917 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Janssen R And D | PARAFON FORTE DSC | chlorzoxazone | TABLET;ORAL | 011529-002 | Jun 15, 1987 | DISCN | Yes | No | ➤ Sign Up | ➤ Sign Up | |||||
| Janssen R And D | INTELENCE | etravirine | TABLET;ORAL | 022187-001 | Jan 18, 2008 | RX | Yes | No | 6,878,717 | ➤ Sign Up | ➤ Sign Up | ||||
| Janssen R And D | INTELENCE | etravirine | TABLET;ORAL | 022187-001 | Jan 18, 2008 | RX | Yes | No | 7,887,845 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Non-Orange Book US Patents for Janssen R And D
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 7,015,221 | 2,4-disubstituted triazine derivatives | ➤ Sign Up |
| 8,530,655 | HIV replication inhibiting pyrimidines | ➤ Sign Up |
| 6,638,932 | 2,4-disubstituted triazine derivatives | ➤ Sign Up |
| 7,241,458 | Antiviral compositions | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Janssen R And D Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| African Intellectual Property Organization (OAPI) | 11675 | ➤ Sign Up |
| Portugal | 1002795 | ➤ Sign Up |
| Israel | 169949 | ➤ Sign Up |
| China | 1322198 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Janssen R And D Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2009000003 | Germany | ➤ Sign Up | PRODUCT NAME: ETRAVIRIN UND DESSEN ADDITIONSSALZE; REGISTRATION NO/DATE: EU/1/08/468/001 20080828 |
| 1002795/01 | Switzerland | ➤ Sign Up | PRODUCT NAME: ETRAVIRIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 58483 13.05.2008 |
| C0004 | France | ➤ Sign Up | PRODUCT NAME: ETRAVIRINE AINSI QUE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/08/468/001 DU 20080828; REGISTRATION NO/DATE AT EEC: EU/1/08/468/001 DU 20080828 |
| 5/2009 | Austria | ➤ Sign Up | PRODUCT NAME: ETRAVIRIN UND DESSEN ADDITIONSSALZE |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.
